Data from the Global TB Report shows Zimbabwe is making meaningful progress in combating TB, with significant improvements across incidence rates, treatment outcomes, and TB/HIV co-infection figures.
WHO’s latest findings note that TB incidence in Zimbabwe has fallen to 203 per 100,000, marking a 3.8% reduction from 2023.
Dr. Fungai Kavenga, Deputy Director of the AIDS & TB Unit in the Ministry of Health and Child Care, welcomed the recorded improvements but cautioned that the battle to end the disease is far from over.
“I’m proud to share Zimbabwe’s continued progress in the fight against TB,” Dr. Kavenga stated, highlighting key achievements:
- Treatment Success: Treatment success for new and relapse TB cases improved to 91%, up from 89% in 2023.
- Drug-Resistant TB: Treatment success for RR/MDR-TB (Rifampicin-resistant/Multi-drug resistant TB) cases also improved, rising from 64% in the 2021 cohort to 68% in the 2022 cohort.
- Co-infection Rate: TB/HIV co-infection rates fell to 49%, down from 51%.
- Universal Access: The nation has recorded universal access to rapid diagnostics at the time of diagnosis and universal access to rifampicin susceptibility testing for all bacteriologically confirmed pulmonary TB.
Global Progress Slow, Funding Remains Inadequate
Despite regional success stories, TB remains a major global public health problem. Progress in reducing the overall disease burden still falls far short of the 2030 targets in most parts of the world.
Globally, 2024 saw the absolute number of people falling ill with TB decrease for the first time since 2020. This follows three consecutive years of increases (2021–2023) due to COVID-related disruptions. The total of 10.7 million people falling ill was a small (1%) reduction from 10.8 million in 2023, though it remains above the 2020 level of 10.3 million.
However, the report sounds an alarm regarding the stagnating funding landscape that now threatens this delicate global progress.
Funding for the TB response is described as grossly inadequate. Funding for prevention, diagnosis, and treatment amounted to US$5.9 billion in 2024, while TB research received US$1.2 billion in 2023. These figures represent only 27% and 24% of the global targets of US$22 billion and US$5 billion annually by 2027, respectively. The WHO warns that anticipated cuts to international donor funding from 2025 onwards pose a direct and severe threat to the overall TB response in many high-burden countries.